Perindopril Erbumine NDC 65862-287

NDC codes

FDA NDC Directory

Product NDC (as listed)65862-287Labeler and product segments. Claims need a package NDC.

Product NDC at billing width65862-0287Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
65862-287-01	65862028701	100 TABLET in 1 BOTTLE (65862-287-01)Marketed from Nov 10, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Perindopril Erbumine
Generic name (nonproprietary): perindopril erbumine
Active ingredients: Perindopril erbumine — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 079070
Marketing start: Nov 10, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 65862-287_46f1c769-2a77-4526-8303-0abc4a78d53eSPL ID 46f1c769-2a77-4526-8303-0abc4a78d53eSPL set ID 87768fbf-7c63-47da-8925-0316f343d6efRxCUI 854925, 854984, 854988UNII 1964X464OJ
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N465862028701 followed by a unit qualifier and the quantity

Package 65862-0287-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 13, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. (1.1) Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. (1.2) 1.1 Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 1.2 Stable Coronary Artery Disease Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 079070

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 079070
Product	Strength	Form · route	Labeler	Product NDC
Perindopril Erbumine	Perindopril erbumine 2 mg/1	TabletOral	Aurobindo Pharma Limited	65862-286
Perindopril Erbumine	Perindopril erbumine 8 mg/1	TabletOral	Aurobindo Pharma Limited	65862-288